{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:04:01Z","timestamp":1791903841113,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Long\u2010term <jats:italic>Helicobacter pylori<\/jats:italic> infection increases the risk of gastric malignancies. Since the symptoms for <jats:italic>H.\u2009pylori<\/jats:italic> gastritis, as well as for several malignancies, may be nonexisting or highly unspecific, even <jats:italic>H.\u2009pylori\u2010<\/jats:italic>positive subjects with underlying malignancies may receive eradication therapy. The aim was to assess the incidence of gastrointestinal and various other malignancies in individuals after eradication therapy for <jats:italic>H.\u2009pylori<\/jats:italic> infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A cohort of 217,554 subjects (120,344 women and 97,210 men), who had purchased specific combinations of drugs for <jats:italic>H.\u2009pylori<\/jats:italic> eradication therapy in 1994\u20132004, was identified by the Finnish National Prescription Registry and followed for cancer incidence until the end of 2008 (1.89\u2009million person\u2010years at risk).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 22,398 malignancies were identified in the cohort. In both genders, for the first 6\u2009months after drug prescription, the standardized incidence ratios (SIRs) were between 5 and 32 for gastric, colorectal, and pancreatic cancers, and 2 and 3 for several other malignancies. Although later on the SIRs of most malignancies fell rapidly, those of gastric noncardia and lung cancers remained elevated up to 5\u2009years of follow\u2010up. The only SIRs below unity were seen in men for gastric cancers (cardia 0.61, 95% CI: 0.37\u20130.95; intestinal noncardia 0.74, 95% CI: 0.56\u20130.97) during the post\u2010therapy period covering years 5\u201315.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Incidence levels significantly above the population rates were detected for many malignancies. Although eradication of <jats:italic>H.\u2009pylori<\/jats:italic> may have a long\u2010lasting protective effect against gastric cancer, <jats:italic>H.\u2009pylori<\/jats:italic> therapy may postpone the detection of malignancies possibly underlying unspecific gastrointestinal symptoms. Therefore, it should be emphasized that the diagnostic work\u2010up for malignancies should not be stopped in case of detection and treatment of <jats:italic>H.\u2009pylori<\/jats:italic> infection.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hel.12979","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T11:59:12Z","timestamp":1680523152000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Incidence of gastrointestinal malignancies increases in persons received eradication therapy for <i>Helicobacter pylori<\/i>: A cohort study"],"prefix":"10.1111","volume":"28","author":[{"given":"Timo U.","family":"Kosunen","sequence":"first","affiliation":[{"name":"Department of Bacteriology and Immunology, Haartman Institute University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9486-4245","authenticated-orcid":false,"given":"Anna A.","family":"Nieminen","sequence":"additional","affiliation":[{"name":"Department of Surgery Helsinki University Hospital and University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arto","family":"Kokkola","sequence":"additional","affiliation":[{"name":"Department of Surgery Helsinki University Hospital and University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perttu","family":"Arkkila","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Helsinki University Hospital and University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Pukkala","sequence":"additional","affiliation":[{"name":"Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research  Helsinki Finland"},{"name":"Health Sciences Unit, Faculty of Social Sciences Tampere University  Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilpi","family":"Rautelin","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Department of Medical Sciences Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.4.626"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.3.347"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91409-F"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.114504"},{"key":"e_1_2_8_6_1","first-page":"1","article-title":"Biological agents. Volume 100 B. A review of human carcinogens","volume":"100","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2012","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2009.05.002"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu240"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021832"},{"key":"e_1_2_8_10_1","first-page":"1","article-title":"Schistosomes, liver flukes and Helicobacter pylori. IARC working Group on the evaluation of carcinogenic risks to humans. Lyon, 7\u201314 June 1994","volume":"61","year":"1994","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/26.4.880"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2009.00727.x"},{"key":"e_1_2_8_13_1","volume-title":"Tobacco Smoke and Involuntary Smoking","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2004"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312288"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-9-705"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.2.187"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-2-200907210-00009"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25337"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0347-9"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009836"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e328358ad9b"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520802273041"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322368"},{"issue":"7","key":"e_1_2_8_24_1","article-title":"Helicobacter pylori eradication for the prevention of gastric neoplasia","volume":"7","author":"Ford AC","year":"2020","journal-title":"Cochrane Database of Syst Rev"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32610"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.04.022"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268897007565"},{"key":"e_1_2_8_28_1","volume-title":"NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 9.2 (23.06.2022)","author":"Lar\u00f8nningen S","year":"2022"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1714"},{"key":"e_1_2_8_30_1","first-page":"1","volume-title":"Contributions to Epidemiology and Biostatistics","author":"Pukkala E","year":"1995"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/cki115"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24223-1_2"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hel.12979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T22:49:36Z","timestamp":1692485376000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hel.12979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/hel.12979"],"URL":"https:\/\/doi.org\/10.1111\/hel.12979","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"2022-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12979"}}